tert-butyl (S)-(1-amino-1-oxopropan-2-yl)(methyl)carbamate | 344609-43-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-(1-amino-1-oxopropan-2-yl)(methyl)carbamate
• 英文别名: tert-butyl N-[(1S)-2-amino-1-methyl-2-oxoethyl]-N-methylcarbamate；((S)-1-Carbamoyl-ethyl)-methyl-carbamic acid tert-butyl ester；tert-butyl N-[(2S)-1-amino-1-oxopropan-2-yl]-N-methylcarbamate
• CAS: 344609-43-4
• 化学式: C₉H₁₈N₂O₃
• 分子量: 202.254
• InChiKey: OEFCBLXGLAZEMS-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-(1-amino-1-oxopropan-2-yl)(methyl)carbamate 在 甲醇 、 乙酰氯 作用下， 以 1,4-二氧六环 为溶剂， 反应 23.0h， 以100%的产率得到N-Me-Ala-NH2*HCl
  参考文献：
  名称：

  Majusculamides A 和 B 及其类似物对成骨活性的构效关系研究。

  摘要：

  我们发现从在冲绳收集的海洋蓝藻中分离的majusculamide A ( 1 ) 和 majusculamide B ( 2 ) 诱导 MC3T3-E1 细胞中的成骨细胞分化。尽管majusculamide A ( 1 ) 仅在C-19 立体中心具有不同的构型，带有甲基，但与majusculamide B ( 2 )相比，1的作用强于2。我们合成了 majusculamides 的一些类似物 ( 3 – 15) 并评估这些类似物的成骨活性。majusculamide类似物的结构-活性关系研究表明的甲基和配置在C-19和数量的取代基的在C-20 majusculamide A（的性质1）可以是用于的成骨细胞分化诱导作用重要1。

  DOI：

  10.1021/acs.jnatprod.0c00441
• 作为产物：
  描述：

  N-^tBOC-N-methyl-L-alanine methyl ester 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以100%的产率得到tert-butyl (S)-(1-amino-1-oxopropan-2-yl)(methyl)carbamate
  参考文献：
  名称：

  Synthesis, Structure–Activity Analysis, and Biological Evaluation of Sanguinamide B Analogues

  摘要：

  We report the first synthesis of sanguinamide B analogues. Substituting N-methylated (N-Me) amino acids, glycine (Gly), and L- or D-phenylalanine (Phe) into the backbone of sanguinamide B showed that only L- and D-Phe residues controlled the macrocycle conformation. The N-methylated and glycine analogues all had multiple conformations, whereas the L- and D-Phe derivatives only had a single conformation. Testing of all conformer analogues showed that inclusion of an L- or D-Phe was a superior design element than incorporating the N-Me moiety that is often utilized to control macrocyclic conformation. Finally, we show that there is an ideal Phe residue (in this case L-Phe) for generating compounds that have the greatest inhibitory effect on bacterial motility. Our data support the hypothesis that the macrocyclic conformation is dictated by the benzyl moiety requiring a "pseudoequatorial" position, and all other energy considerations are secondary.

  DOI：

  10.1021/jo3017499

文献信息

• Peptide Derivative
  申请人：Sakurada Shinobu

  公开号：US20080009448A1

  公开（公告）日：2008-01-10

  A pharmaceutical composition comprising a peptide derivative or its pharmaceutical equivalent salt having a general formula, R 1 N═C(R 2 )-AA 1 -AA 2 -AA 3 -AA 4 -Y, in which R 1 is such as a hydrogen, R 2 is such as a methyl group, Y is such as a methylamino group, AA 1 is such as a tyrosine group, AA 2 is such as a D-arginine group, AA 3 is such as a phenylalanine group, and AA 4 is such as a N-methyllysine group has analgesic activity against a variety of pains on both subcutaneous and oral administration.

  一种包括肽衍生物或其药用等效盐的药物组合物，其具有一般式R1N═C(R2)-AA1-AA2-AA3-AA4-Y，其中R1为氢，R2为甲基基团，Y为甲基氨基基团，AA1为酪氨酸基团，AA2为D-精氨酸基团，AA3为苯丙氨酸基团，AA4为N-甲基赖氨酸基团，在皮下和口服给药时对各种疼痛具有镇痛活性。
• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。
• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CYSTEINE PROTEASE
  申请人：MEDIVIR AB

  公开号：WO2005066180A1

  公开（公告）日：2005-07-21

  A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  一个公式为(II)的化合物，其中R1和R2中的一个是卤素，另一个是H或卤素；R3是C1-C4直链或支链，可选择氟代的烷基；R4是H；或者R3与R4和相邻的骨架碳一起定义：一个螺环C5-C7环烷基，可选地用1至3个卤素、羟基、C1-C4烷基或C1-C4卤代烷基中的取代基取代；或者可选地用亚甲基桥接；或者是一个具有O、NRa、S、S(=O)2等异原子的C4-C6饱和杂环；其中Ra是H、C1-C4烷基或CH3C(=O)；R5独立地选择自H或甲基；E是-C(=O)-、-S(=O)m-、-NR5S(=O)m-、-NR5C(=O)-、-OC(=O)-；R6是稳定的、可选择取代的、单环或双环的、碳环或杂环；m独立地为0、1或2；是猫hepsin K的抑制剂，并且在骨质疏松症的治疗或预防中有用。
• BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20140057924A1

  公开（公告）日：2014-02-27

  Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed.

  抑制IAP蛋白质的抑制剂和含有这些抑制剂的组合物被披露。还披露了使用IAP蛋白质抑制剂治疗疾病和状况的方法，其中抑制IAP蛋白质提供益处，如癌症等。
• [EN] BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2012143725A1

  公开（公告）日：2012-10-26

  The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  该发明涉及式(I)的双环杂环化合物，或其互变异构体或立体化学异构体，N-氧化物，药用可接受的盐或其溶剂化合物；其中R1、R2、R3、A、W、U和V如本文所定义；以及包含该化合物的药物组合物，并将该化合物用于治疗疾病，例如癌症。